Spironolactone (Teva is a brand of this generic medicine) is commonly used to help manage symptoms associated with several conditions characterized by periods of heightened symptoms.

The medicine is relevant for easing symptomatic discomfort related to edematous conditions, where it assists in easing the overall symptom burden of fluid retention (edema) linked to conditions like congestive heart failure, liver cirrhosis (including ascites), and nephrotic syndrome (kidney disease). The medicine is applied in addressing conditions where symptoms may intensify temporarily, and supports the patient during difficult episodes.

It is also relevant for easing symptoms related to high blood pressure (hypertension). It is commonly used for managing conditions that involve episodic or fluctuating manifestations, as well as for the diagnosis and long-term maintenance therapy of primary hyperaldosteronism (a condition where the adrenal gland produces too much aldosterone).

The range of conditions it is commonly used for includes: fluid retention (edema) linked to heart or liver conditions, high blood pressure, and hyperaldosteronism. Patients often experience the benefit of supportive relief that helps ease the overall symptom burden during symptomatic phases.

“This medicine is commonly used to help with symptoms that create noticeable functional strain.”

---

Quick Fact: Relief for Fluid Retention and High Blood Pressure

The eligibility for Spironolactone Teva is strictly governed by regulatory documentation, primarily based on avoiding the risk of severe hyperkalemia (high blood potassium) and significant organ dysfunction. Use is formally classified into three categories: allowed, restricted, or prohibited.

Prohibited Populations (Contraindications)

The medicine must not be used by patients with:

• Hyperkalemia (high blood potassium levels).
• Addison's disease (adrenal gland failure).
• Severe Renal Impairment (severe kidney dysfunction, typically eGFR <30 mL/min).
• Anuria (inability to pass urine) or acute renal insufficiency.
• Known Hypersensitivity or allergy to the drug.

Age and Condition-Based Restrictions

Population Group	Regulatory Status	Constraint Summary
Adults	Generally Allowed	Standard eligible population.
Older Adults (Geriatric)	Conditional Use	Requires caution and lowest possible starting dose due to potential age-related organ impairment.
Children/Paediatric	Conditional Use	Use is established but often requires specialist supervision (paediatrician); contraindicated if moderate-to-severe kidney disease is present.
Pregnancy	Not Recommended	Generally avoided; used only if benefits clearly outweigh risks (animal data suggests risk).
Lactation	Conditional Restriction	Metabolites are excreted into breast milk; official guidance recommends deciding between discontinuing the medicine or breastfeeding.

Patients with hepatic impairment (liver disorders) are eligible but require careful monitoring due to altered drug metabolism and excretion.

Interactions with other medicines and products

Spironolactone's primary interaction risk is hyperkalemia (elevated serum potassium), which can be life-threatening. This risk is greatly increased when combined with other products that raise or conserve potassium.

• Potassium-Increasing Products: Concomitant use with potassium supplements, potassium-sparing diuretics (e.g., eplerenone, triamterene, amiloride), ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), or heparin/low molecular weight heparin is generally associated with a high risk of hyperkalemia and requires frequent monitoring. The combination with eplerenone is generally contraindicated.

• Lithium: Spironolactone can reduce the renal clearance of lithium, which may lead to dangerously increased serum lithium levels and toxicity. Lithium levels must be monitored closely upon initiation or dose change of spironolactone.

• Digoxin: Spironolactone and its metabolites can interfere with certain laboratory tests (radioimmunoassays) used to measure digoxin levels. The actual clinical significance of spironolactone's effect on digoxin exposure is not fully established, but interference with measurement is documented.

• Other Noteworthy Interactions: Concomitant use with the cancer drug abiraterone is not recommended due to the potential for spironolactone to bind to the androgen receptor, which may compromise abiraterone's effectiveness. Cholestyramine in combination with spironolactone has been associated with hyperkalemic metabolic acidosis. NSAIDs, including acetylsalicylic acid (aspirin), may reduce the diuretic and antihypertensive efficacy of spironolactone.

The action of Spironolactone Teva is defined by two primary mechanistic domains that influence key physiological regulatory systems.

Targeted Modulation of Fluid and Electrolyte Balance

This domain covers the drug's role as a Mineralocorticoid Receptor (MR) antagonist in the kidney. By competitively blocking the MR, it prevents the binding and action of the natural hormone aldosterone in the distal renal tubules and collecting ducts. This mechanism increases the excretion of sodium ( Na^+) and water while simultaneously promoting the conservation of potassium ( K^+). This action results in a decrease in total fluid volume and a net retention of potassium ions.

---

Interaction with Steroid Hormone Signaling

This domain describes the drug's distinct action as an antagonist at the Androgen Receptor (AR), and its interaction with the Progesterone Receptor (PR). This mechanism interferes with the cellular response to specific sex hormones like testosterone and DHT in target tissues. This interference produces alterations in peripheral hormonal signaling pathways.

Spironolactone Teva is administered exclusively via the oral route using tablet or liquid suspension formulations. The essential administration principle is to take the medicine with a meal or food to significantly enhance the absorption of the active substance.

Dosing regimens are highly specific to the condition. For essential hypertension, the starting dose typically ranges from 50 mg to 100 mg daily, while the regimen for severe heart failure usually initiates at 25 mg once daily. For chronic conditions, the medication is commonly used as a long-term maintenance therapy. When the prescribed daily dose exceeds 100 mg, it is generally administered in divided doses. To minimize disruption from increased nocturnal fluid output, the final dose of a divided regimen should be taken no later than 4 p.m.

Dosage adjustments require adherence to mandated timeframes. For example, in the management of hypertension, the current dose must be maintained for at least two weeks before any therapeutic adjustment is considered. High-level principles are specified for specific populations: pediatric dosing is calculated based on body weight in mg/kg, and for older adults, treatment must always begin at the lowest possible dose.

Research Evidence / Overview of Studies for Spironolactone Teva

Evidence for Use in Congestive Heart Failure

Research has extensively examined Spironolactone in adult patients with moderate to severe heart failure where the heart's pumping ability is reduced (HFrEF). The studies conducted during periods of increased symptom activity included multicenter RCTs with follow-up durations up to several years. Researchers monitored outcomes related to systemic or functional imbalance, specifically tracking the time to major events such as cardiovascular death or the need for hospitalization related to heart failure.

The findings describe patterns observed in the studies over several years of observation. Research highlights measurements taken during the study period in the frequency of hospital admissions for heart failure. The evidence also contributes to understanding symptom patterns by monitoring patient outcomes reflecting daily functioning, such as measurements in the New York Heart Association (NYHA) functional class. However, long-term effects are not fully established beyond the duration of the initial studies.

Evidence for Use in Resistant Hypertension

Spironolactone was evaluated in adult patients with high blood pressure classified as resistant, meaning their blood pressure levels remained high despite using three or more other types of blood pressure medications. The studies measured outcomes related to systemic or functional imbalance, such as the precise measurements in both office-measured and 24-hour ambulatory blood pressure monitoring (ABPM) readings.

The research so far describes measured blood pressure parameters taken from both systolic and diastolic readings. Findings describe patterns observed in the studies where the measured blood pressure showed shifts in the observed populations. Follow-up durations were limited in many of these resistant hypertension trials, often spanning less than one year. Therefore, long-term effects are not fully established concerning the impact of these observed blood pressure shifts on later cardiovascular events.

Evidence in Special Populations and Uncertainties

Spironolactone was evaluated in special populations where the drug's processing or effect may differ, such as older adults and pediatric patients. Data for certain groups remain insufficient, and subgroup findings are uncertain for complex conditions like significant kidney disease, as these groups were often excluded from the main assessment trials.

Data are still emerging regarding the overall patterns observed with Spironolactone, and comparative evidence is lacking for some of the drug's applications when compared to certain newer therapies. The methodology of the evidence varies across studies, with some key information coming from older, smaller trials.

Common questions about Spironolactone Teva (FAQ)

Q: Does Spironolactone Teva treat conditions other than high blood pressure or heart failure?

According to the official product information, Spironolactone Teva is indicated for several conditions beyond hypertension and heart failure. These uses include managing primary hyperaldosteronism, a hormonal condition that causes fluid retention. It is also used to address edema, or swelling, associated with conditions like liver cirrhosis or nephrotic syndrome, and certain types of low potassium (hypokalemia).

Q: How long does it typically take for the effects of Spironolactone Teva to be noticeable?

Official information indicates that the onset of the diuretic effect of Spironolactone is not immediate due to its mechanism of action. The action is considered delayed. For certain conditions, the peak effect may take 48 hours or longer to become fully noticeable after the first dose.

Q: Are skin rashes a side effect that requires immediate attention according to patient leaflets?

Official regulatory documents list a range of adverse skin reactions, including common effects such as rash and hives (urticaria). The official safety profile also notes the occurrence of rare but potentially life-threatening severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Q: What types of over-the-counter pain relievers or supplements may interact with Spironolactone Teva?

Regulatory documents describe potential interactions with several products that can increase the risk of elevated potassium levels (hyperkalemia). These include certain non-steroidal anti-inflammatory drugs (NSAIDs). It is also noted that the medicine may interact with potassium supplements or salt substitutes containing potassium.

Q: Is this medicine listed as being suitable for people with specific types of kidney problems?

Eligibility is conditional for individuals with kidney problems. The medicine is formally contraindicated, meaning it must not be used, in patients with severe renal impairment (severe kidney dysfunction) or anuria (inability to pass urine). Official labeling indicates caution and close monitoring is advised by healthcare professionals for use in individuals with less severe kidney problems.

Q: What are the descriptive signs of dangerously high potassium levels mentioned in patient information?

Patient information describes the potential signs of elevated potassium levels (hyperkalemia) that a person might notice. These include physical symptoms such as muscle weakness and a tingling feeling. Additionally, the official warnings highlight cardiovascular signs like a slow or irregular heartbeat and shortness of breath.

Q: Are there different available strengths of Spironolactone Teva tablets?

The active ingredient, Spironolactone, is commercially produced in various tablet strengths to accommodate different dosing needs. According to official drug information, available strengths typically include 12.5 mg, 25 mg, 50 mg, and 100 mg tablets.

Q: What is the chemical name for the active ingredient in Spironolactone Teva?

Spironolactone is the active ingredient's international nonproprietary name. According to the chemical description provided in regulatory labeling, the formal chemical name is 17 -hydroxy-7alpha -mercapto-3-oxo-17alpha -pregn-4-ene-21-carboxylic acid gamma -lactone acetate. This formal name describes the precise molecular structure of the compound.

Q: What should a patient know about blood test monitoring while taking Spironolactone Teva?

Because of the potential for electrolyte and metabolic changes, official documents describe that blood monitoring is required periodically. Regulatory guidance specifies the monitoring of serum potassium levels, other key electrolytes, and kidney function. Monitoring of blood glucose may also be included for certain patients.

Q: What information is available regarding hair thinning as a possible effect of Spironolactone Teva?

Alopecia, which is the medical term for hair loss or hair thinning, is listed in official regulatory documents as an adverse reaction associated with the use of Spironolactone. This information is classified as part of the overall safety profile of the medicine.

Q: Does official guidance mention any food restrictions, particularly those high in potassium, while using this medication?

Official guidance notes caution is advised regarding a diet rich in potassium due to the risk of elevated potassium when taking this medicine. The use of salt substitutes containing potassium is also noted as a restriction in regulatory information.

Q: What is the general advice about alcohol consumption while taking Spironolactone Teva?

According to drug interaction databases, alcohol may cause additive effects in lowering blood pressure when combined with this medication. This combination may increase the risk of experiencing adverse effects such as dizziness and fainting.

Q: What is the official guidance on what to do if a person misses a dose of Spironolactone Teva?

Official guidance provides general instructions for a missed dose, which typically state that a missed dose should be taken when remembered only if it is not almost time for the next dose. The guidance advises against taking two doses to compensate for the one that was missed.

Q: Is it necessary to drink extra water while taking Spironolactone Teva, according to official advice?

Official information notes that due to the medicine causing a loss of body fluid, fluid management is important. Guidance refers patients to their healthcare provider regarding fluid intake when excessive fluid loss occurs, such as from severe vomiting or heavy sweating.

Q: What is the official guidance on modifying the Spironolactone Teva tablet (e.g., crushing or chewing)?

Official guidance specifies that the tablet form must be swallowed whole. Regulatory information advises against chewing or crushing the tablet, as this is necessary to ensure the correct release and absorption of the medicine.

Q: Is there a 'Black Box Warning' or similar serious caution associated with Spironolactone Teva in FDA labeling?

The U.S. FDA prescribing information for this medicine does include a Boxed Warning, which is a type of serious caution. This warning notes that Spironolactone has been shown to be a tumorigen, meaning capable of causing tumors, in chronic toxicity studies conducted in rats.

Q: What is the official information regarding gradually stopping or discontinuing Spironolactone Teva?

Official guidance specifies that consultation with a healthcare provider is necessary before discontinuing the medication. This is noted because stopping the medicine prematurely without medical guidance may cause the underlying condition to worsen.

Q: Does Spironolactone Teva affect blood sugar levels, according to product information?

Official product labeling notes the potential for metabolic abnormalities. Therefore, the guidance includes the requirement for blood glucose levels to be monitored periodically, especially in patients who may be at risk for developing blood sugar fluctuations.

Q: Is it mentioned in official documents if Spironolactone Teva can impact a person's ability to drive?

Official information states that due to potential effects like dizziness, the medicine may affect coordination, reaction time, or judgment. Regulatory guidance advises against driving or operating machinery until the full effect of the medicine is known.

Storage and Disposal Requirements for Spironolactone Tablets

Spironolactone tablets must be stored according to official regulatory specifications to maintain stability and effectiveness.

Storage Conditions

• Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
• Protection: The medicine must be protected from light and stored away from excess moisture.
• Container: Keep the product in a tight, light-resistant container, with the lid kept tightly closed.
• Child Safety: It is mandatory to keep the container out of the sight and reach of children.

Disposal

Unused or expired Spironolactone should be taken to a drug take-back program or mail-back program if available. If a take-back option is not accessible, the medicine can be disposed of in the household trash by mixing it with an unappealing substance and placing it in a sealed container before discarding. Official guidance instructs against throwing medicines away via wastewater.